New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation
Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Review Of Cardiovascular Therapy 2012, 10: 1471-1480. PMID: 23253272, DOI: 10.1586/erc.12.148.Peer-Reviewed Original ResearchConceptsNew oral anticoagulantsParoxysmal atrial fibrillationOral anticoagulantsNonparoxysmal atrial fibrillationAtrial fibrillationHeart failureStroke preventionNew anticoagulantsContemporary phase III trialsAdditional prognostic benefitPhase III trialsPresence of diabetesNew drugsImpact of genderIII trialsPrognostic benefitDiabetes mellitusAnticoagulantsPatientsWarfarinEvent ratesCardiovascular medicineFibrillationMellitusDiabetesAnticoagulation in Atrial Fibrillation.
Ahmad Y, Lip GY. Anticoagulation in Atrial Fibrillation. Arrhythmia & Electrophysiology Review 2012, 1: 12-16. PMID: 26835023, PMCID: PMC4711491, DOI: 10.15420/aer.2012.1.12.Peer-Reviewed Original ResearchAtrial fibrillationMost thromboembolic complicationsEfficacy of warfarinNew oral anticoagulantsRisk stratification schemesOral anticoagulationAntithrombotic therapyOral anticoagulantsSevere strokeThromboembolic riskThromboembolic complicationsAF patientsAnticoagulant monitoringCommon arrhythmiaNew anticoagulantsWorse outcomesImproved outcomesNew agentsPatientsAF treatmentStratification schemesAnticoagulationDose variabilityAnticoagulantsWarfarin